You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Sequent Scientific gains on selling stake in Strides Pharma

Capital Market 

Sequent Scientific rose 1.23% to Rs 147.95 after the pharmaceutical company completed the sale of investments held in Strides Pharma Science on Friday, 25 September 2020.

The proceeds of the sale (net of taxes) will be predominantly utilised to consolidate the company's shareholding in Provet Veteriner Urunleri San. Ve Tic. A. S., Turkey (Provet) by acquiring 40% stake held by Dr. Husein Aydin in Provet, with the balance to be used to pare the outstanding debt of the company, Sequent Scientific said. The announcement was made after market hours on Friday, 25 September 2020.

Post the acquisition of minority stake, which is expected to close on or before October 31, 2020, Provet will become a wholly owned subsidiary of the company.

On 12 August 2020, Sequent Scientific had proposed the sale of investments held by the company in Strides Pharma Science to Pronomz Ventures LLP.

On 22 September 2020, Sequent Scientific entered into definitive agreement with Dr Huseyin Aydin for the acquisition of 40% stake from him in Provet for $17.10 million.

Sequent Scientific is the largest Indian pure-play animal healthcare company with global operations. Sequent provides animal health Active Pharmaceutical Ingredients (API), formulations, and analytical services in over 100 countries, with more than 1,700 employees and manufacturing operations in India, Spain, Turkey, Germany and Brazil.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, September 28 2020. 09:21 IST